1. Home
  2. FSUN vs SNDX Comparison

FSUN vs SNDX Comparison

Compare FSUN & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

FSUN

FirstSun Capital Bancorp

HOLD

Current Price

$39.38

Market Cap

1.6B

Sector

Finance

ML Signal

HOLD

Logo Syndax Pharmaceuticals Inc.

SNDX

Syndax Pharmaceuticals Inc.

HOLD

Current Price

$17.62

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FSUN
SNDX
Founded
1892
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.8B
IPO Year
2017
2014

Fundamental Metrics

Financial Performance
Metric
FSUN
SNDX
Price
$39.38
$17.62
Analyst Decision
Buy
Strong Buy
Analyst Count
3
13
Target Price
$45.00
$38.69
AVG Volume (30 Days)
250.2K
1.3M
Earning Date
04-27-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
29.00
11.56
EPS
N/A
N/A
Revenue
N/A
$172,352,000.00
Revenue This Year
$79.34
$107.19
Revenue Next Year
$14.67
$41.88
P/E Ratio
N/A
N/A
Revenue Growth
N/A
627.84
52 Week Low
$29.95
$13.00
52 Week High
$42.34
$25.59

Technical Indicators

Market Signals
Indicator
FSUN
SNDX
Relative Strength Index (RSI) 46.45 34.27
Support Level $39.29 $16.93
Resistance Level $40.46 $22.40
Average True Range (ATR) 0.76 0.71
MACD -0.20 -0.24
Stochastic Oscillator 29.60 6.00

Price Performance

Historical Comparison
FSUN
SNDX

About FSUN FirstSun Capital Bancorp

Firstsun Capital Bancorp is the financial holding company. It provides a full range of deposit, lending, treasury management, wealth management, and online banking products and services. The company operates in two segments; Banking operations and mortgage operations, the majority of which are generated by the banking operations segment. The Banking segment originates loans and provides deposits and fee based services to consumer, business, and mortgage lending customers. Products offered include a full range of commercial and consumer banking and financial services. The Mortgage Operations segment originates, sells, services, and manages market risk from changes in interest rates on one-to-four family residential mortgage loans.

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Share on Social Networks: